Hivast F 145mg/10mg Tablet is a combination lipid-lowering medication containing Fenofibrate 145mg and Rosuvastatin 10mg, indicated for the management of dyslipidemia and mixed hyperlipidemia. Fenofibrate, a fibric acid derivative, primarily acts by activating peroxisome proliferator-activated receptor alpha (PPARα), which enhances lipolysis and elimination of triglyceride-rich particles, thereby reducing serum triglycerides and increasing high-density lipoprotein cholesterol (HDL-C). Rosuvastatin, a potent HMG-CoA reductase inhibitor, decreases cholesterol synthesis in the liver, leading to significant reductions in low-density lipoprotein cholesterol (LDL-C) and total cholesterol levels. The combination therapy offers a synergistic effect, effectively improving lipid profiles in patients with elevated LDL-C, triglycerides, and low HDL-C, thereby reducing the risk of cardiovascular events. Hivast F is indicated for patients who require simultaneous management of hypercholesterolemia and hypertriglyceridemia not adequately controlled by monotherapy. It should be administered under medical supervision with regular monitoring of lipid levels, liver function tests, and renal parameters. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in pregnancy and active liver disease. Adverse effects may include myopathy, elevated liver enzymes, and gastrointestinal disturbances.